Insulet Corporation $PODD Shares Sold by Aberdeen Group plc

Key Points

• Aberdeen Group plc has reduced its holdings in Insulet Corporation (NASDAQ:PODD) by 15.3%, now owning approximately 0.20% of the company with a value of $45 million.
• Several other investors, including Nissay Asset Management and Mather Group, have also increased their stakes in Insulet during the recent quarters.
• Wall Street analysts have raised their price targets for Insulet, with estimates ranging from $300 to $415, reflecting a consensus target price of $347.67.

Aberdeen Group plc lowered its holdings in Insulet Corporation (NASDAQ:PODD - Free Report) by 15.3% in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 143,251 shares of the medical instruments supplier's stock after selling 25,932 shares during the period. Aberdeen Group plc owned approximately 0.20% of Insulet worth $45,007,000 as of its most recent SEC filing.

Several other large investors also recently made changes to their positions in the business. Nissay Asset Management Corp Japan ADV boosted its stake in Insulet by 0.6% during the 1st quarter. Nissay Asset Management Corp Japan ADV now owns 8,462 shares of the medical instruments supplier's stock valued at $2,222,000 after acquiring an additional 48 shares during the last quarter. Mather Group LLC. boosted its stake in Insulet by 4.4% during the 2nd quarter. Mather Group LLC. now owns 1,147 shares of the medical instruments supplier's stock valued at $360,000 after acquiring an additional 48 shares during the last quarter. Brooklyn Investment Group boosted its stake in Insulet by 7.0% during the 1st quarter. Brooklyn Investment Group now owns 795 shares of the medical instruments supplier's stock valued at $209,000 after acquiring an additional 52 shares during the last quarter. Cooper Financial Group boosted its stake in Insulet by 5.7% during the 1st quarter. Cooper Financial Group now owns 1,079 shares of the medical instruments supplier's stock valued at $283,000 after acquiring an additional 58 shares during the last quarter. Finally, HighTower Advisors LLC boosted its stake in Insulet by 2.1% during the 1st quarter. HighTower Advisors LLC now owns 2,882 shares of the medical instruments supplier's stock valued at $757,000 after acquiring an additional 60 shares during the last quarter.

Wall Street Analyst Weigh In

PODD has been the topic of a number of recent research reports. Piper Sandler raised their price target on shares of Insulet from $320.00 to $360.00 and gave the stock an "overweight" rating in a research report on Tuesday, September 16th. Barclays raised their price target on shares of Insulet from $266.00 to $300.00 and gave the stock an "equal weight" rating in a research report on Thursday, August 21st. Oppenheimer raised their price target on shares of Insulet from $324.00 to $365.00 and gave the stock an "outperform" rating in a research report on Monday, September 8th. Royal Bank Of Canada raised their price target on shares of Insulet from $350.00 to $365.00 and gave the stock an "outperform" rating in a research report on Friday. Finally, JPMorgan Chase & Co. raised their price target on shares of Insulet from $340.00 to $415.00 and gave the stock an "overweight" rating in a research report on Friday, September 12th. Seventeen analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus target price of $347.67.

Insulet Trading Down 1.8%

Shares of NASDAQ:PODD opened at $314.52 on Monday. The company has a market cap of $22.14 billion, a PE ratio of 95.60, a P/E/G ratio of 2.61 and a beta of 1.40. The company's 50-day moving average price is $323.75 and its 200 day moving average price is $300.64. Insulet Corporation has a fifty-two week low of $226.50 and a fifty-two week high of $353.50. The company has a quick ratio of 1.81, a current ratio of 2.26 and a debt-to-equity ratio of 0.64.

Insulet (NASDAQ:PODD - Get Free Report) last issued its quarterly earnings data on Thursday, August 7th. The medical instruments supplier reported $1.17 earnings per share for the quarter, beating the consensus estimate of $0.92 by $0.25. The firm had revenue of $649.10 million for the quarter, compared to the consensus estimate of $612.31 million. Insulet had a net margin of 10.01% and a return on equity of 23.78%. Insulet's quarterly revenue was up 32.9% compared to the same quarter last year. During the same period last year, the firm posted $0.55 EPS. Insulet has set its FY 2025 guidance at EPS. Q3 2025 guidance at EPS. Sell-side analysts anticipate that Insulet Corporation will post 3.92 earnings per share for the current year.

Insider Activity

In other Insulet news, SVP Prem Singh sold 687 shares of the firm's stock in a transaction dated Monday, September 8th. The shares were sold at an average price of $347.49, for a total transaction of $238,725.63. Following the transaction, the senior vice president owned 3,456 shares of the company's stock, valued at approximately $1,200,925.44. This trade represents a 16.58% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, SVP Laetitia Cousin sold 797 shares of the firm's stock in a transaction dated Monday, September 8th. The shares were sold at an average price of $348.81, for a total transaction of $278,001.57. Following the transaction, the senior vice president directly owned 3,890 shares in the company, valued at approximately $1,356,870.90. The trade was a 17.00% decrease in their position. The disclosure for this sale can be found here. 0.39% of the stock is currently owned by company insiders.

Insulet Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.

Want to see what other hedge funds are holding PODD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Insulet Corporation (NASDAQ:PODD - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.